# US 10,869,917 B2 · A*03 restricted peptides for use in immunotherapy against cancers and related methods > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,869,917 B2 - Document ID: US10869917B2 - Status: Granted - Kind: B2 - Application number: 16/917,381 - Filed: 2020-06-30 - Published: 2020-10-15 - Granted: 2020-12-22 - Earliest claimed: 2018-06-29 - Assignees: Immatics Biotechnologies GmbH - Applicants: Immatics Biotechnologies GmbH - Inventors: Colette Song; Linus Backert; Heiko Schuster; Daniel Johannes Kowalewski; Oliver Schoor; Jens Fritsche; Toni Weinschenk; Harpreet Singh - Web page: https://patentgrep.com/patent/US10869917B2 ## CPC - A61K 39/0011: {Cancer antigens} - A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00) - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - A61K 40/42: Cancer antigens - A61P 35/00: Antineoplastic agents - C07K 7/06: having 5 to 11 amino acids - C07K 14/70539: {MHC-molecules, e.g. HLA-molecules} - C07K 16/2833: {against MHC-molecules, e.g. HLA-molecules} - C07K 16/30: from tumour cells - C12N 5/0636: {T lymphocytes} - A61K 2039/5158: {Antigen-pulsed cells, e.g. T-cells} - C07K 2317/32: specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) ## Abstract The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. ## Claims ### Claim 1 A method of treating a patient who has breast cancer overexpressing ESR1 polypeptide comprising the amino acid sequence of SEQ ID NO: 32, comprising administering to said patient a composition comprising a population of activated T cells that kill the cancer cells, wherein the activated T cells are cytotoxic T cells produced by contacting CD8+ T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SEQ ID NO: 32, in a complex with an MHC class I molecule on the surface of the antigen presenting cell in vitro, for a period of time sufficient to activate said T cell. ### Claim 2 (depends on 1) The method of claim 1, wherein the T cells are autologous to the patient. ### Claim 3 (depends on 1) The method of claim 1, wherein the T cells are obtained from a healthy donor. ### Claim 4 (depends on 1) The method of claim 1, wherein the T cells are derived from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. ### Claim 5 (depends on 1) The method of claim 1, further comprising expanding T cells in vitro. ### Claim 6 (depends on 5) The method of claim 5, wherein the expansion is in the presence of an anti-CD28 antibody and IL-12. ### Claim 7 (depends on 1) The method of claim 1, wherein the composition further comprises an adjuvant. ### Claim 8 (depends on 7) The method of claim 7, wherein the adjuvant is selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG, oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. ### Claim 9 (depends on 8) The method of claim 8, wherein the adjuvant comprises IL-2. ### Claim 10 (depends on 8) The method of claim 8, wherein the adjuvant comprises IL-7. ### Claim 11 (depends on 8) The method of claim 8, wherein the adjuvant comprises IL-15. ### Claim 12 (depends on 8) The method of claim 8, wherein the adjuvant comprises IL-21. ### Claim 13 (depends on 1) The method of claim 1, wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide. ### Claim 14 (depends on 13) The method of claim 13, wherein the antigen presenting cell is a dendritic cell or a macrophage. ### Claim 15 A method of eliciting an immune response in a patient who has breast cancer overexpressing ESR1 polypeptide comprising the amino acid sequence of SEQ ID NO: 32, comprising administering to said patient a composition comprising a population of activated T cells that kill the cancer cells, wherein the activated T cells are cytotoxic T cells produced by contacting CD8+ T cells with an antigen presenting cell that presents a peptide consisting of the amino acid sequence of SEQ ID NO: 32, in a complex with an MHC class I molecule on the surface of the antigen presenting cell in vitro, for a period of time sufficient to activate said T cell. ### Claim 16 (depends on 15) The method of claim 15, wherein the composition further comprises an adjuvant selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG, oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23. ### Claim 17 (depends on 16) The method of claim 16, wherein the adjuvant comprises IL-2. ### Claim 18 (depends on 16) The method of claim 16, wherein the adjuvant comprises IL-7. ### Claim 19 (depends on 16) The method of claim 16, wherein the adjuvant comprises IL-15. ### Claim 20 (depends on 16) The method of claim 16, wherein the adjuvant comprises IL-21.